Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.40
Bid: 1.30
Ask: 1.50
Change: 0.00 (0.00%)
Spread: 0.20 (15.385%)
Open: 1.45
High: 1.45
Low: 1.40
Prev. Close: 1.40
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Installation at Barrow Neurological Institute

11 Dec 2018 07:00

RNS Number : 9988J
IQ-AI Limited
11 December 2018
 

IQ-AI Ltd

("IQ-AI" or the "Company")

Imaging Biometrics® installation at Barrow Neurological Institute

Imaging Biometrics®, LLC ("IB"), a subsidiary of IQ-AI Limited (LON:IQAI), announced today that Barrow Neurological Institute: Dignity Health, St. Joseph's Hospital and Medical Center ("BNI") has installed a new IB Rad Tech software platform to help assess treatment response for patients with brain tumors. BNI has led the way in the development of cutting-edge diagnosis, treatment, and neurosurgical procedures for patients with brain tumors. Every year, Barrow treats thousands of patients with brain tumors, including some of the most difficult cases in the world. IB Rad Tech was chosen for its ability to efficiently generate quantitative maps of enhancing regions of tumor (Delta T1) and fractional tumor burden ("FTB"). IB's perfusion-derived FTB maps have been shown to aid clinicians in distinguishing tumor from non-tumor tissue.

IB Rad Tech offers customised workflows that automate the generation of sophisticated maps, outputs quality assurance indices, and can allow manual acknowledgement and intervention during intermediate processing steps. For example, one workflow used in generating quantitative Delta T1 and FTB maps relies on an exclusive machine-learned calibration technology termed "standardisation", which works for all platforms and field strengths. This step has proven superior to conventional normalisation techniques as it eliminates the need for the manual placement of regions of interest (ROIs) by radiology staff or physicians thereby reducing error and improving workflow efficiencies.

David Smith, CEO of IB, said, "Using this automated normalisation algorithm within an IB Rad Tech workflow enables objective longitudinal assessment and can help assess whether a certain treatment protocol is working for brain tumor patients. Removing the variability of the manually-placed ROI is a more repeatable and faster method to do inter- and intra-study comparisons for multi-center clinical trials as well."

"Without IB Rad Tech, we would not be able to process the high volume of studies we see at our site," said Dr. John Karis, MD, Director of MRI and brain imaging for the Department of Neuroradiology at Barrow Neurological Institute, Dignity Health St. Joseph's Hospital and Medical Center. "Our MR Technologists are now able to quickly and consistently generate IB's advanced maps, and the clinicians trust the science on which Delta T1 and FTBs are based", added Josef Debbins, PhD, Staff Scientist, Keller Center for Imaging Innovation at Barrow.

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

IQ-AI Limited

Trevor Brown/Vinod Kaushal/Qu Li

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Fungai Ndoro

Tel: 020 7220 9797

 

Barrow Neurological Institute / Dignity Health St. Joseph's Hospital and Medical Center has led the way in the development of cutting-edge diagnosis, treatment, and neurosurgical procedures for patients with brain tumors. Every year, Barrow treats thousands of patients with brain tumors, including some of the most difficult cases in the world. Since 1962, Barrow has grown into one of the premiere destinations in the world for neurology and neurosurgery. Experienced, highly skilled, and comprehensive teams of neurological specialists provide a complete spectrum of care-from diagnosis through outpatient neurorehabilitation-under one roof. Barrow Neurological Institute: Discover. Educate. Heal.

Imaging Biometrics, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides -visualisation and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

IQ-AI Limited (Ticker:IQAI) is the parent company of StoneChecker® and Imaging Biometrics® focused on advanced and state of the art medical software and services. (www.iq-ai.ltd).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRGGGUAPUPRGWU
Date   Source Headline
28th Oct 20089:38 amRNSEPT Disclosure
27th Oct 20082:14 pmRNSEPT Disclosure - Replacement
27th Oct 200810:38 amRNSEPT Disclosure
24th Oct 20089:23 amRNSEPT Disclosure
23rd Oct 20089:35 amRNSEPT Disclosure
21st Oct 20082:11 pmRNSInterim Management Statement
17th Oct 20089:24 amRNSEPT Disclosure
14th Oct 200811:36 amRNSEPT Disclosure
14th Oct 20089:31 amRNSEPT Disclosure
10th Oct 20089:44 amRNSEPT Disclosure
9th Oct 20089:26 amRNSEPT Disclosure
8th Oct 20088:53 amRNSEPT Disclosure
6th Oct 200810:48 amRNSEPT Disclosure
3rd Oct 20089:14 amBUSRule 8.3 - Flying Brands
1st Oct 20088:31 amRNSEPT Disclosure
30th Sep 20089:00 amRNSBlocklisting Interim Review
25th Sep 20088:42 amRNSEPT Disclosure
24th Sep 200810:47 amRNSEPT Disclosure
16th Sep 20088:32 amRNSEPT Disclosure
15th Sep 20089:21 amRNSEPT Disclosure
12th Sep 20089:49 amRNSEPT Disclosure - Replacement
12th Sep 20089:10 amRNSEPT Disclosure - Correction
12th Sep 20088:53 amRNSEPT Disclosure
11th Sep 20085:40 pmBUSRule 8.3 - Flying Brands
3rd Sep 20088:35 amRNSEPT Disclosure
2nd Sep 20088:54 amRNSEPT Disclosure
28th Aug 200810:07 amRNSEPT Disclosure
27th Aug 20083:17 pmBUSRule 8.3 - Flying Brands
27th Aug 20089:28 amRNSEPT Disclosure
26th Aug 200811:04 amRNSEPT Disclosure
26th Aug 20089:53 amRNSEPT Disclosure
22nd Aug 20089:16 amRNSEPT Disclosure
22nd Aug 20088:31 amRNSEPT Disclosure
21st Aug 20088:42 amRNSEPT Disclosure
20th Aug 20089:02 amRNSEPT Disclosure
19th Aug 20089:11 amRNSEPT Disclosure
18th Aug 200810:42 amRNSEPT Disclosure
18th Aug 20089:52 amRNSEPT Disclosure
14th Aug 20089:25 amRNSEPT Disclosure
13th Aug 20082:53 pmPRNRule 8.3 - Flying Brands
13th Aug 200810:17 amBUSRule 8.3 - Flying Brands
13th Aug 20089:06 amRNSEPT Disclosure
12th Aug 20089:22 amBUSRule 8.3 - Flying Brands
12th Aug 20088:34 amRNSEPT Disclosure
12th Aug 20088:23 amRNSEPT Disclosure
11th Aug 20081:24 pmPRNRule 8.3 - Flying Brands Limited
11th Aug 200811:00 amRNSEPT Disclosure
11th Aug 200810:23 amBUSRule 8.3 - Flying Brands
11th Aug 20088:58 amRNSEPT Disclosure
8th Aug 200810:17 amRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.